Introduction

This analysis examines the historical and forecast performance for Allergan in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Allergan's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for Allergan over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Allergan's performance against key rivals in the prescription pharmaceutical sector* Understand how Allergan has exploited side effects and cross-marketing opportunities to maximize returns from its specialist sales force* Gain insight into how re-formulations of existing brands are not expected to be sufficient to maintain sales growth in the tight ophthalmic space

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Allergan: PharmaVitae forecasts at a glance
Strategic insight
Botox plays a central role in Allergan’s synergistic expansion
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Acquired by SmithKline Beckman
Allergan spun-out from SmithKline Beckman
Acquisition of Oculinum
Divestment of Allergan Humphrey
Divestment of contact lens businesses
Five acquisitions were made in and around 1995
Allergan Specialty Therapeutics spun-out
Allergan Specialty Therapeutics re-acquired
Bardeen Sciences set-up
Advanced Medical Optics spun-out
Bardeen Sciences acquired
Oculex acquired
Acquistition of Inamed
Groupe Corneal Laboratoires acquired
EndoArt acquired
Acquisition of Esprit Pharma
Acquisition of Serica Technologies
Current corporate structure
Pharmaceuticals
Allergan Medical
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Note regarding full-year 2010 financial data
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Key product overview
Botox
Restasis
Lumigan franchise
Alphagan franchise
Ozurdex
Latisse
APPENDIX
References
R&D pipeline
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]